Protagonist Corp (PTGX) - מקדם חוב לטווח ארוך להון

Current price action for Protagonist Therapeutics (PTGX) reflects the performance of the company, which developed pill-based alternatives to injections under the leadership of Dinesh Patel. The business relies on the commercial implementation of peptide drugs, where the launch of rusfertide and royalties from J&J will serve as key growth drivers. The debt-to-equity ratio stands at 0.01, with finances based on tranches from counterparties rather than consistent product sales.

This ratio determines the company's degree of dependence on debt with a maturity of over one year relative to its equity, reflecting the financial stability of the structure. By analyzing this long-term leverage, an investor sees the actual debt load, which for Protagonist Therapeutics (PTGX) is critical when financing the costly development of oral peptide drugs for the treatment of severe immune pathologies.